Anti-MAdCAM1 Reference Antibody (ontamalimab) is used as a research and development tool to study the role of the MAdCAM-1 protein, which is involved in chronic inflammation, particularly in intestinal diseases such as Crohn’s disease and ulcerative colitis. This antibody inhibits the binding of lymphocytes to the intestinal vascular endothelium, offering potential to reduce inflammation in intestinal tissues.

In therapeutic contexts, ontamalimab is developed as a targeted biologic that blocks MAdCAM-1 function, reducing immune cell migration to inflammation sites and improving symptoms. Clinical studies demonstrate good response rates and increased remission in patients.

Additionally, this antibody serves as a reference standard for developing commercial antibodies and quality control in manufacturing, ensuring specificity and efficacy of similar products.